Logo

Predicant Licenses Caliper Microfluidics Technology for Proteomic Tests

Jan 06, 2005

NEW YORK, Jan. 6 (GenomeWeb News) - Predicant Biosciences has licensed microfluidics patents from Caliper Life Sciences for use in the analysis of proteins by mass spectrometry, the companies said today.

 

Under the non-exclusive licensing deal, Predicant, of South San Francisco, Calif., plans to use Caliper's microfluidics technology to separate proteins from blood for diagnostic tests based on protein patterns that it is developing.

 

The agreement is part of Caliper's new outlicensing strategy, "with the goal of permeating the life sciences, diagnostics and other industries with out microfluidics technologies," Caliper CEO Kevin Hrusovsky said in a company statement.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.